AR054382A1 - Formulacion de compresion directa de un inhibidor de dipeptidil-peptidasa iv y una glitazona y proceso - Google Patents
Formulacion de compresion directa de un inhibidor de dipeptidil-peptidasa iv y una glitazona y procesoInfo
- Publication number
- AR054382A1 AR054382A1 ARP060102392A ARP060102392A AR054382A1 AR 054382 A1 AR054382 A1 AR 054382A1 AR P060102392 A ARP060102392 A AR P060102392A AR P060102392 A ARP060102392 A AR P060102392A AR 054382 A1 AR054382 A1 AR 054382A1
- Authority
- AR
- Argentina
- Prior art keywords
- percent
- inhibitor
- dry weight
- glitazone
- weight basis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Un inhibidor de dipeptil-peptidasa IV (referido en la presente como DPP-IV), que puede ser del 98.5 al 100 por ciento puro, es un fármaco de dosis alta capaz de comprimirse directamente con una glitazona y excipientes específicos en formas de dosificacion solidas, tales como tabletas y cápsulas, que tienen las características deseadas, de dureza, capacidad de desintegracion, y disolucion aceptable. Los excipientes utilizados en la formulacion mejoran las propiedades de flujo y compactacion del fármaco y de la mezcla formadora de tabletas. El flujo optimo contribuye a un llenado uniforme del troquel y al control del peso. El aglutinante utilizado asegura suficientes propiedades cohesivas que permiten que el inhibidor de dipeptidil peptidasa IV se comprima empleando el método de compresion directa. Las tabletas producidas proporcionan un perfil de disolucion in vitro aceptable. Una composicion farmacéutica, la cual comprende: (a) del 5 al 65 por ciento, sobre una base de peso seco, de dos ingredientes activos consistentes en: i) un inhibidor de dipeptidil-peptidasa IV en forma libre o en forma de sal de adicion de ácido; ii) una glitazona, en forma libre o en forma de sal de adicion de ácido; (b) del 30 al 95 por ciento en peso, sobre una base de peso seca, de un diluyente farmacéuticamente aceptable; (c) del 0 al 20 por ciento en peso, sobre una base de peso seco, de un desintegrante farmacéuticamente aceptable; y opcionalmente, (d) del 0.1 al 10 por ciento en peso, sobre una base de peso seco, de un lubricante farmacéuticamente aceptable.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68973905P | 2005-06-10 | 2005-06-10 | |
US69052705P | 2005-06-14 | 2005-06-14 | |
US69081405P | 2005-06-15 | 2005-06-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR054382A1 true AR054382A1 (es) | 2007-06-20 |
Family
ID=37198127
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060102392A AR054382A1 (es) | 2005-06-10 | 2006-06-08 | Formulacion de compresion directa de un inhibidor de dipeptidil-peptidasa iv y una glitazona y proceso |
Country Status (14)
Country | Link |
---|---|
US (1) | US20080193529A1 (es) |
EP (1) | EP1893236A2 (es) |
JP (1) | JP2008543767A (es) |
KR (1) | KR20080018257A (es) |
AR (1) | AR054382A1 (es) |
AU (2) | AU2006258013A1 (es) |
BR (1) | BRPI0613567A2 (es) |
CA (1) | CA2610412A1 (es) |
GT (1) | GT200600218A (es) |
MX (1) | MX2007015612A (es) |
PE (1) | PE20070165A1 (es) |
SA (1) | SA06270158B1 (es) |
TW (1) | TW200716175A (es) |
WO (1) | WO2006135693A2 (es) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
JOP20180109A1 (ar) * | 2005-09-29 | 2019-01-30 | Novartis Ag | تركيبة جديدة |
PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
MX2008014024A (es) | 2006-05-04 | 2008-11-14 | Boehringer Ingelheim Int | Formas poliformas. |
MY147596A (en) | 2007-02-01 | 2012-12-31 | Takeda Pharmaceutical | Solid preparation comprising alogliptin and pioglitazone |
PE20090597A1 (es) * | 2007-08-16 | 2009-06-06 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un derivado de pirazol-o-glucosido |
PE20090938A1 (es) | 2007-08-16 | 2009-08-08 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo |
PE20140960A1 (es) * | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
AU2014262269B2 (en) * | 2008-04-03 | 2017-02-02 | Boehringer Ingelheim International Gmbh | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
KR20200118243A (ko) | 2008-08-06 | 2020-10-14 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
WO2010029089A2 (en) | 2008-09-10 | 2010-03-18 | Boehringer Ingelheim International Gmbh | Combination therapy for the treatment of diabetes and related conditions |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
KR101054911B1 (ko) | 2008-10-17 | 2011-08-05 | 동아제약주식회사 | 디펩티딜펩티다아제-ⅳ의 활성을 저해하는 화합물 및 다른 항당뇨 또는 항비만 약물을 유효성분으로 함유하는 당뇨 또는 비만의 예방 및 치료용 약학적 조성물 |
WO2010072776A1 (en) | 2008-12-23 | 2010-07-01 | Boehringer Ingelheim International Gmbh | Salt forms of organic compound |
AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
UA102429C2 (ru) | 2009-02-13 | 2013-07-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Фармацевтическая композиция, которая включает ингибитор sglt-2, ингибитор дпп-iv и другой антидиабетический агент, и ее применение |
UY32427A (es) * | 2009-02-13 | 2010-09-30 | Boheringer Ingelheim Internat Gmbh | Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma |
SI2459531T1 (sl) * | 2009-07-31 | 2020-02-28 | Krka, D.D., Novo Mesto | Granulat, ki obsega vildagliptin, in postopek njegove priprave |
CN102753161A (zh) | 2009-11-27 | 2012-10-24 | 贝林格尔.英格海姆国际有限公司 | 基因型糖尿病患者利用dpp-iv抑制剂例如利拉利汀的治疗 |
ES2935300T3 (es) | 2010-05-05 | 2023-03-03 | Boehringer Ingelheim Int | Combiterapia |
MX2012012438A (es) * | 2010-05-05 | 2012-11-29 | Boehringer Ingelheim Int | Formulaciones farmaceuticas que comprenden pioglitazona y linagliptina. |
CN106975074A (zh) | 2010-06-24 | 2017-07-25 | 勃林格殷格翰国际有限公司 | 糖尿病治疗 |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
UY33937A (es) | 2011-03-07 | 2012-09-28 | Boehringer Ingelheim Int | Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina |
WO2013010964A1 (en) | 2011-07-15 | 2013-01-24 | Boehringer Ingelheim International Gmbh | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
WO2013171167A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
CN102657626B (zh) * | 2012-05-23 | 2013-07-17 | 重庆康刻尔制药有限公司 | 一种盐酸吡格列酮药物组合片剂 |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
WO2014193528A1 (en) * | 2013-04-29 | 2014-12-04 | Anovel Pharmaceuticals, Llc | Amorphous dosage forms and methods |
JP5922310B2 (ja) * | 2013-07-25 | 2016-05-24 | 株式会社三和化学研究所 | 医薬製剤 |
US9526728B2 (en) | 2014-02-28 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Medical use of a DPP-4 inhibitor |
BR112018072401A2 (pt) | 2016-06-10 | 2019-02-19 | Boehringer Ingelheim International Gmbh | combinações de linagliptina e metformina |
JP7379189B2 (ja) | 2020-01-31 | 2023-11-14 | 沢井製薬株式会社 | ビルダグリプチン含有コーティング粒子、ビルダグリプチン含有口腔内崩壊錠、ビルダグリプチン含有コーティング粒子の製造方法及びビルダグリプチン含有口腔内崩壊錠の製造方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI238064B (en) * | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
CN1977842A (zh) * | 2000-01-21 | 2007-06-13 | 诺瓦提斯公司 | 含有二肽基肽酶-iv抑制剂和抗糖尿病药物的联合形式 |
GB0014969D0 (en) * | 2000-06-19 | 2000-08-09 | Smithkline Beecham Plc | Novel method of treatment |
US7510728B2 (en) * | 2000-10-06 | 2009-03-31 | Takeda Pharmaceutical Company Limited | Solid preparations |
US6573287B2 (en) * | 2001-04-12 | 2003-06-03 | Bristo-Myers Squibb Company | 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method |
DE10308355A1 (de) * | 2003-02-27 | 2004-12-23 | Aventis Pharma Deutschland Gmbh | Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel |
US20040186046A1 (en) * | 2003-03-17 | 2004-09-23 | Pfizer Inc | Treatment of type 1 diabetes with PDE5 inhibitors |
US20070072810A1 (en) * | 2003-10-03 | 2007-03-29 | Takeda Pharmaceutical Company, Limited | Agent for treating diabetes |
US20090253752A1 (en) * | 2004-10-25 | 2009-10-08 | Bryan Burkey | Combination of dpp-iv inhibitor, ppar antidiabetic and metmorfin |
-
2006
- 2006-05-24 GT GT200600218A patent/GT200600218A/es unknown
- 2006-06-03 SA SA6270158A patent/SA06270158B1/ar unknown
- 2006-06-08 AR ARP060102392A patent/AR054382A1/es unknown
- 2006-06-08 AU AU2006258013A patent/AU2006258013A1/en not_active Abandoned
- 2006-06-08 WO PCT/US2006/022336 patent/WO2006135693A2/en active Application Filing
- 2006-06-08 MX MX2007015612A patent/MX2007015612A/es unknown
- 2006-06-08 US US11/916,490 patent/US20080193529A1/en not_active Abandoned
- 2006-06-08 EP EP06772588A patent/EP1893236A2/en not_active Withdrawn
- 2006-06-08 BR BRPI0613567-6A patent/BRPI0613567A2/pt not_active IP Right Cessation
- 2006-06-08 JP JP2008515929A patent/JP2008543767A/ja active Pending
- 2006-06-08 KR KR1020087000577A patent/KR20080018257A/ko not_active Application Discontinuation
- 2006-06-08 CA CA002610412A patent/CA2610412A1/en not_active Abandoned
- 2006-06-08 PE PE2006000642A patent/PE20070165A1/es not_active Application Discontinuation
- 2006-06-09 TW TW095120636A patent/TW200716175A/zh unknown
-
2010
- 2010-08-24 AU AU2010212516A patent/AU2010212516A1/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
GT200600218A (es) | 2007-03-28 |
EP1893236A2 (en) | 2008-03-05 |
SA06270158B1 (ar) | 2010-10-23 |
AU2006258013A1 (en) | 2006-12-21 |
JP2008543767A (ja) | 2008-12-04 |
PE20070165A1 (es) | 2007-03-09 |
WO2006135693A3 (en) | 2007-02-15 |
AU2010212516A1 (en) | 2010-09-16 |
US20080193529A1 (en) | 2008-08-14 |
WO2006135693A2 (en) | 2006-12-21 |
KR20080018257A (ko) | 2008-02-27 |
BRPI0613567A2 (pt) | 2011-01-18 |
TW200716175A (en) | 2007-05-01 |
CA2610412A1 (en) | 2006-12-21 |
MX2007015612A (es) | 2008-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR054382A1 (es) | Formulacion de compresion directa de un inhibidor de dipeptidil-peptidasa iv y una glitazona y proceso | |
AR049000A1 (es) | Formulacion para compresion directa y proceso para la preparacion de una tableta directamente comprimida | |
AR052878A1 (es) | Formulacion de compresion directa y proceso | |
RU2009106681A (ru) | Гранулированные фармацевтические композиции | |
PE20140960A1 (es) | Formulaciones que comprenden un inhibidor de dpp4 | |
AU2014363599B2 (en) | Orally disintegrating solid dosage unit containing an estetrol component | |
US20190030033A1 (en) | Pharmaceutical composition containing jak kinase inhibitor or pharmaceutically acceptable salt thereof | |
AR070731A1 (es) | Composicion farmaceutica para farmacos poco solubles | |
PE20060075A1 (es) | Composiciones farmaceuticas de alisciren | |
ES2916649T1 (es) | Composiciones y usos para el tratamiento de la esclerosis múltiple | |
RU2013121788A (ru) | Ингибиторы репликации вич | |
AR061166A1 (es) | Composiciones farmaceuticas para la liberacion sostenida de fenilferina | |
PE20040104A1 (es) | Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco | |
AR095159A2 (es) | Una composición farmacéutica en forma de cápsula para administración oral | |
AR061790A1 (es) | Composicion farmaceutica solida para la administracion oral, formulaciones de comprimidos de liberacion inmediata de un antagonista del receptor de trombina, y su uso en la manufactura de un medicamento | |
AR077284A1 (es) | Composiciones de dosis fija farmaceuticas solidas que comprenden irbesartan y amlodipina, su preparacion y su aplicacion terapeutica | |
AR105184A1 (es) | Comprimidos de liberación inmediata que contienen un fármaco y procesos para formar los comprimidos | |
ES2624231T3 (es) | Coadyuvante de formación de comprimidos a base de lactosa y celulosa | |
NZ594669A (en) | Oral composition of Vorinostat | |
AR048970A1 (es) | Formulacion farmaceutica solida | |
RU2015129714A (ru) | Композиция в форме таблеток, содержащая гидрохлорид цинакалцета | |
AR043370A1 (es) | Composiciones farmaceuticas de administracion oral y metodos para evitar la interaccion alimento -droga | |
RU2014146936A (ru) | Композиции с немедленным высвобождением лекарственного средства | |
AR099137A2 (es) | Formulación para compresión directa y proceso | |
PE20110923A1 (es) | Formulaciones de desintegracion rapida pre-compactadas de compuestos con baja biodisponibilidad oral |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |